Chad B. Stein

Chad B. Stein

Auto-generated profile, based on publicly available information

Chad B. Stein

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2020 in Molecular Cell
Verified
Journal Article
Closed access
KHKai-Lieh Huang
Kai-Lieh Huang
DJDavid Jee
David Jee
CSChad B. Stein
Chad B. Stein
NENathan D. Elrod
Nathan D. Elrod
THTelmo Henriques
Telmo Henriques
EWEric J. Wagner
Eric J. Wagner

19 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSChad B. Stein
Chad B. Stein
PGPavol Genzor
Pavol Genzor
SMSanga Mitra
Sanga Mitra
AEAlexandra R. Elchert
Alexandra R. Elchert
JIJonathan J. Ipsaro
Jonathan J. Ipsaro
AHAstrid D. Haase
Astrid D. Haase
PIWI-interacting RNAs (piRNAs) are at the center of a small RNA-based immune system that defends genomes against the deleterious action of mobile genetic elements (transposons). PiRNAs are highly variable in sequence with extensive targeting potential. Their diversity is restricted by their preference to start with a Uridine (U) at the 5′ most position (1U-bias), a bias that remains poorly understood. Here we uncover that the 1U-bias of Piwi-piRNAs is established by consecutive discrimination against all nucleotides but U, first during piRNA biogenesis and then upon interaction with Piwi’s specificity loop. Sequence preferences during piRNA processing also restrict U across the piRNA body with the potential to directly impact target recognition. Overall, the uncovered signatures could modulate specificity and efficacy of piRNA-mediated transposon restriction, and provide a substrate for purifying selection in the ongoing arms race between genomes and their mobile parasites.

30 March 2022 in Nature
Verified
Journal Article
Open access
PDF file
HZHaining Zhou
Haining Zhou
CSChad B. Stein
Chad B. Stein
TSTiasha A. Shafiq
Tiasha A. Shafiq
GSGergana Shipkovenska
Gergana Shipkovenska
MKMarian Kalocsay
Marian Kalocsay
DMDanesh Moazed
Danesh Moazed
Polycomb repressive complexes 1 and 2 (PRC1 and PRC2) are histone-modifying and -binding complexes that mediate the formation of facultative heterochromatin and are required for silencing of developmental genes and maintenance of cell fate1–3. Multiple pathways of RNA decay work together to establish and maintain heterochromatin in fission yeast, including a recently identified role for a conserved RNA-degradation complex known as the rixosome or RIX1 complex4–6. Whether RNA degradation also has a role in the stability of mammalian heterochromatin remains unknown. Here we show that the rixosome contributes to silencing of many Polycomb targets in human cells. The rixosome associates with human PRC complexes and is enriched at promoters of Polycomb target genes. Depletion of either the rixosome or Polycomb results in accumulation of paused and elongating RNA polymerase at Polycomb target genes. We identify point mutations in the RING1B subunit of PRC1 that disrupt the interaction between PRC1 and the rixosome and result in diminished silencing, suggesting that direct recruitment of the rixosome to chromatin is required for silencing. Finally, we show that the RNA endonuclease and kinase activities of the rixosome and the downstream XRN2 exoribonuclease, which degrades RNAs with 5′ monophosphate groups generated by the rixosome, are required for silencing. Our findings suggest that rixosomal degradation of nascent RNA is conserved from fission yeast to human, with a primary role in RNA degradation at facultative heterochromatin in human cells.